Clinical trials: Lipemia
Hypercholesterolemia
Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003
To assess the longer term safety, tolerability, and LDL C lowering efficacy after 52 weeks of additional treatment with LIB003 with subcutaneous (SC) dosing every 4 weeks (Q4W)
- Trial name
- NCT03847974
- Testing
- LIB003
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- LIB Therapeutics LLC
Hypercholesterolemia
A Clinical Trial Study to Evaluate Efficacy and Safety of Atorvastatin in Korean Patients With Hypercholesterolemia
The purpose of this study is to compare the efficacy and safety of atorvastatin generic product with reference drug.
- Trial name
- NCT01081548
- Testing
- atorvastatin
- Where
- South Korea
- Volunteers
- 17 people
- Sponsor
- Yonsei University
Type 2 Diabetes Mellitus
Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension
Primary Objective: To evaluate the effect of irbesartan/atorvastatin fixed-dose combination comparing to each irbesartan and atorvastatin on flow mediated dilation change in type 2 diabetic patients diagnosed with hyperlipidemia…
- Trial name
- NCT02842359
- Testing
- Irbesartan/atorvastatin fixed dose combination, Irbesartan SR47436, Atorvastatin
- Where
- South Korea
- Volunteers
- 11 people
- Sponsor
- Sanofi
Overweight or Obesity
Probiotic Influence on Obesity-Related Lipidemia
This study aims to investigate the effects of Bifidobacterium breve BBr60 on key health indicators in overweight and obese adults.
- Trial name
- NCT06305650
- Testing
- Probiotic
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Hypertension, Hyperlipidemia
A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin
An open-label, randomized, single-dose, 2X3X3 partial replicate, crossover study to compare the pharmacokinetics and safety between a fixed dose combination of Fimasartan/Amlodipine/Rosuvastatin and Co-administration of a fixed…
- Trial name
- NCT02995720
- Testing
- Fimasartan/Amlodipine combination drug, Rosuvastatin
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hyperlipidemia
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
Researchers designed a study medicine called enlicitide to lower low-density lipoprotein cholesterol (LDL-C). In this study, researchers want to learn about giving enlicitide with another medicine called rosuvastatin.
- Trial name
- NCT07216482
- Testing
- Enlicitide, Rosuvastatin
- Where
- 87 sites in United States, Argentina and 9 more
- Volunteers
- 996 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Hypercholesterolaemia
ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals
24 week open label study to compare the treatment either with rosuvastatin or rosuvastatin plus initiatives to improve compliance.
- Trial name
- NCT00396240
- Testing
- Rosuvastatin, Initiatives to improve compliance
- Volunteers
- 1,294 people
- Sponsor
- AstraZeneca
Atherosclerosis, Hypercholesterolemia
Rosuvastatin Affecting Aortic Valve Endothelium
Recent studies support the hypothesis that aortic stenosis (AS) develops due to atherosclerosis affecting the aortic valve endothelium.
- Trial name
- NCT00114491
- Testing
- Rosuvastatin
- Where
- Portugal
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Hospital Pedro Hispano
Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia
A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)
This study will assess the safety and tolerability of Ezetimibe (EZ) 10 mg/Atorvastatin (Atora) 10 mg and EZ 10mg/Atora 20 mg fixed-dose combination (FDC) in Japanese participants with hypercholesterolemia uncontrolled with…
- Trial name
- NCT02460159
- Testing
- EZ 10 mg/Atorva 20 mg FDC, EZ 10 mg/Atorva 10 mg FDC
- Volunteers
- 135 people
- Sponsor
- Organon and Co
Overweight, Obesity
Effect of Glycemic Load on Body Composition
The aim of this study is to compare the effects of diets with different glycemic load (GL) on body composition and biochemical markers in overweight and obese subjects during a 12-month period.
- Trial name
- NCT00603655
- Testing
- Low glycemic load diet, High glycemic load diet
- Where
- Mexico
- Volunteers
- 29 people
- Sponsor
- Universidad Autonoma de Baja California
Hypertriglyceridaemia
Abnormal Lipids - Causes and Effects
1. At target LDL-C levels, apoB100 concentrations will be higher than recommended levels in the following populations: 1. Tertiary centre lipid clinic patients with raised TG treated with statins. 2.
- Trial name
- NCT02195050
- Where
- United Kingdom
- Volunteers
- 1,396 people
- Sponsor
- Manchester University NHS Foundation Trust
Hypertension, Hyperlipidemia
Cardiovascular Lifestyle Study: Effects and Expense of a Cardiovascular Risk Reduction Clinic in Primary Care
The purpose of this trial is to study the effects on risk reduction and expense of 3 approaches to the care of people with cardiovascular risk factors in a naturalistic primary care environment.
- Conditions
- Hypertension, Hyperlipidemia, Hyperglycemia, Cardiovascular Disease
- Trial name
- NCT00291824
- Testing
- Cardiovascular risk factors and willingness to change
- Where
- Canada
- Volunteers
- 670 people
- Sponsor
- Caroline Medical Group
Hypertriglyceridemia
A First in Human Study of STT-5058, an Antibody That Binds ApoC3
A First in Human Study of STT-5058, an Antibody That Binds ApoC3, investigating single and multiple ascending intravenous doses and ascending subcutaneous doses of STT-5058 in otherwise healthy volunteers with elevated…
- Trial name
- NCT04419688
- Testing
- STT-5058
- Where
- United Kingdom
- Volunteers
- 93 people
- Sponsor
- Staten Biotechnology BV
Cardiovascular Diseases, Heart Diseases
Pharmacogenetics of Hypertriglyceridemia in Hispanics
To study the effect of genes on lipid-lowering drug treatment in hypertriglyceridemia.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Hypertriglyceridemia
- Trial name
- NCT00086437
- Volunteers
- 274 people
- Sponsor
- University of California, Los Angeles
Dyslipidemia
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension
The primary clinical hypothesis is that long-term exposure of evolocumab will be safe and well tolerated in subjects with clinically evident atherosclerotic cardiovascular disease (CVD).
- Trial name
- FOURIER OLE (NCT02867813)
- Testing
- Evolocumab
- Where
- 198 sites in United States, Czechia and 5 more
- Volunteers
- 5,035 people
- Sponsor
- Amgen
Hyperlipidemia, Periodontal Disease
Is There a Relationship Between Hyperlipidemia and Periodontitis?
The aim of present study is to investigate any relationship between hyperlipidemia and periodontal disease regarding the periodontal parameters and plasma lipid parameters, along with age, gender, brushing habit, body mass index…
- Trial name
- NCT02826720
- Testing
- No intervention was applied
- Volunteers
- 160 people
- Sponsor
- Marmara University
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma
Cardiovascular diseases and cancers, the two leading causes of death in Canada, require cholesterol to sustain their progression.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreas Cancer, Metastatic Cancer
- Trial name
- NCT04862260
- Testing
- Cholesterol metabolism disruption
- Where
- 2 sites in Canada
- Volunteers
- 3 people
- Sponsor
- CHU de Quebec-Universite Laval
Familial Hypercholesterolemia
Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy
The purpose of this study is to determine if implitapide, used in conjunction with other lipid-lowering therapies, is safe and effective when compared to placebo in lowering low-density lipoprotein cholesterol (LDL-C) in patients…
- Trial name
- NCT00079859
- Testing
- Implitapide
- Where
- 6 sites in United States, Netherlands and 1 more
- Volunteers
- 120 people
- Sponsor
- Medical Research Laboratories International
Hypercholesterolemia
Observational Study to Evaluate LDL-C Lowering Effect of Ezetimibe (0653-070)
To evaluate the LDL-C lowering in south african patients with primary hypercholesterolaemia after the addition of ezetimibe 10mg /day to ongoing therapy with a statin.
- Trial name
- NCT00457275
- Testing
- MK0653, ezetimibe / Duration of Treatment: 4 Weeks
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Organon and Co
Hypertriglyceridemia
Diazoxide Choline in Hypertriglyceridemia
Hypertriglyceridemia affects 30% of the population in the US. Very high level of triglycerides is a known risk factor for pancreatitis.
- Trial name
- NCT00696475
- Testing
- Diazoxide choline
- Where
- 12 sites in United States
- Volunteers
- 80 people
- Sponsor
- Essentialis, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.